NDA 208169 · Btg Intl
Xuriden
Uridine Triacetate · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Sep 4, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 0 recruiting
FAERS reports
48
28 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 18, 2025.
XURIDEN ® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. XURIDEN is a pyrimidine analog for uridine replacement indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. ( 1 )
Mechanism: Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation (Figure 1). Figure 1: Uridine Triacetate Conversion to Uridine XURIDEN provides uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis. Figure 1
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 2, 2019 Supplement 3 · Efficacy OrphanLetterLabel
- Sep 4, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelSummary ReviewLetter
1 products under this application
- XURIDEN · URIDINE TRIACETATE 2GM/PACKET · GRANULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Uridine Triacetate" as an intervention, any sponsor and status, largest first.
- Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic CancerPivotal-lookingCompleted
Wellstat TherapeuticsIndustry
NCT00024427 · 250 participants · Start Feb 2001 · Primary completion Feb 2006
Drug: fluorouracil; gemcitabine hydrochloride and 1 more · For: Drug/Agent Toxicity by Tissue/Organ; Pancreatic Cancer
Sites: Birmingham, Alabama; Burbank, California; Duarte, California · 29 sites in all
SWOG Cancer Research NetworkResearch network
NCT00004233 · 65 participants · Start Feb 2001 · Primary completion Jan 2007
Drug: fluorouracil; leucovorin calcium and 1 more · For: Esophageal Cancer; Gastric Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 97 sites in all
Wellstat TherapeuticsIndustry
NCT00044785 · 24 participants · Start Aug 2002
Drug: triacetyluridine; fluorouracil and 2 more · For: Solid Tumors
Sites: Baltimore, Maryland
Repligen CorporationIndustry
NCT00060515 · 12 participants
Drug: RG2133 (2',3',5'-tri-O-acetyluridine) · For: Mitochondrial Diseases
- Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic AciduriaPivotal-lookingCompleted
Wellstat TherapeuticsIndustry
NCT02110147 · 4 participants · Start Apr 2014 · Primary completion Dec 2014
Drug: uridine triacetate · For: Hereditary Orotic Aciduria
Sites: Detroit, Michigan; Pittsburgh, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use11
- diarrhoea4
- foetal exposure during pregnancy4
- low birth weight baby4
- mucosal inflammation4
- premature baby4
- thrombocytopenia4
- asthenia3
- drug ineffective3
- drug ineffective for unapproved indication3
- dysphagia3
- gastroenteritis3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Btg Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.